Gilead Sciences (GILD) PT Lifted to $165 at BMO Capital on Strong Q2

July 24, 2014 6:40 AM

BMO Capital analyst Jim Birchenough, M.D.boosted his price target on Outperform-rated Gilead Sciences (NASDAQ: GILD) to $165.00 (from $120.00) following ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found